Point-of-care measurements reveal release of purines into venous blood of stroke patients
Nicholas Dale, Faming Tian, Ravjit Sagoo, Norman Phillips, Chris Imray, Christine Roffe, Nicholas Dale, Faming Tian, Ravjit Sagoo, Norman Phillips, Chris Imray, Christine Roffe
Abstract
Stroke is a leading cause of death and disability. Here, we examine whether point-of-care measurement of the purines, adenosine, inosine and hypoxanthine, which are downstream metabolites of ATP, has potential to assist the diagnosis of stroke. In a prospective observational study, patients who were suspected of having had a stroke, within 4.5 h of symptom onset and still displaying focal neurological symptoms at admission, were recruited. Clinical research staff in the Emergency Departments of two hospitals used a prototype biosensor array, SMARTCap, to measure the purines in the venous blood of stroke patients and healthy controls. In controls, the baseline purines were 7.1 ± (SD) 4.2 μM (n = 52), while in stroke patients, they were 11.6 ± 8.9 μM (n = 76). Using the National Institutes for Stoke Scale (NIHSS) to band the severity of stroke, we found that minor, moderate and severe strokes all gave significant elevation of blood purines above the controls. The purine levels fall over 24 h. This was most marked for patients with haemorrhagic strokes (5.1 ± 3.6 μM, n = 9 after 24 h). The purine levels measured on admission show a significant correlation with the volume of affected brain tissue determined by medical imaging in patients who had not received thrombolysis or mechanical thrombectomy. ClinicalTrials.gov Identifier: NCT02308605.
Keywords: Biosensor; Cerebral ischemia; Point of care; Purines; Stroke.
Conflict of interest statement
ND, FT and CI declare the following conflicts of interest:
ND is a Founder and Director of Sarissa Biomedical Ltd. and has equity in this company. FT is employed by Sarissa Biomedical Ltd., the manufacturer of the biosensors used in the study and related in vitro diagnostic devices. FT, ND and CI are co-inventors on two patent applications relating to the measurement of purines as a diagnostic tool for brain ischaemia.
RS, NP and CR declare that they have no conflict of interest.
Figures
References
- Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability? J Stroke Cerebrovasc Dis. 2004;13(4):171–177. doi: 10.1016/j.jstrokecerebrovasdis.2004.06.003.
- Saka O, McGuire A, Wolfe C. Cost of stroke in the United Kingdom. Age Ageing. 2009;38(1):27–32. doi: 10.1093/ageing/afn281.
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics C, Stroke Statistics S Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322.
- Saver JL. Time is brain—quantified. Stroke. 2006;37(1):263–266. doi: 10.1161/01.STR.0000196957.55928.ab.
- Saver JL, Levine SR. Alteplase for ischaemic stroke—much sooner is much better. Lancet. 2010;375(9727):1667–1668. doi: 10.1016/S0140-6736(10)60634-4.
- Meretoja A, Keshtkaran M, Saver JL, Tatlisumak T, Parsons MW, Kaste M, Davis SM, Donnan GA, Churilov L. Stroke thrombolysis: save a minute, save a day. Stroke. 2014;45(4):1053–1058. doi: 10.1161/STROKEAHA.113.002910.
- Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the biomarker rapid assessment in ischemic injury (BRAIN) study. Stroke. 2009;40(1):77–85. doi: 10.1161/STROKEAHA.108.516377.
- Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, Welsh P, Green A, Andrews M, Graham C, Sandercock P. Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. Cerebrovasc Dis (Basel, Switzerland) 2011;32(2):141–147. doi: 10.1159/000328517.
- Hillered L, Hallstrom A, Segersvard S, Persson L, Ungerstedt U. Dynamics of extracellular metabolites in the striatum after middle cerebral artery occlusion in the rat monitored by intracerebral microdialysis. J Cereb Blood Flow Metab. 1989;9(5):607–616. doi: 10.1038/jcbfm.1989.87.
- Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev. 1992;4(4):346–369.
- Fowler JC. Purine release and inhibition of synaptic transmission during hypoxia and hypoglycemia in rat hippocampal slices. Neurosci Lett. 1993;157(1):83–86. doi: 10.1016/0304-3940(93)90648-5.
- Phillis JW, Smith-Barbour M, O'Regan MH, Perkins LM. Amino acid and purine release in rat brain following temporary middle cerebral artery occlusion. Neurochem Res. 1994;19(9):1125–1130. doi: 10.1007/BF00965145.
- Latini S, Bordoni F, Pedata F, Corradetti R. Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br J Pharmacol. 1999;127(3):729–739. doi: 10.1038/sj.bjp.0702591.
- Melani A, Pantoni L, Corsi C, Bianchi L, Monopoli A, Bertorelli R, Pepeu G, Pedata F. Striatal outflow of adenosine, excitatory amino acids, gamma-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: correlations with neurological deficit and histopathological damage. Stroke. 1999;30(11):2448–2454. doi: 10.1161/01.STR.30.11.2448.
- Dale N, Pearson T, Frenguelli BG. Direct measurement of adenosine release during hypoxia in the CA1 region of the rat hippocampal slice. J Physiol-London. 2000;526(1):143–155. doi: 10.1111/j.1469-7793.2000.00143.x.
- Pearson T, Nuritova F, Caldwell D, Dale N, Frenguelli BG. A depletable pool of adenosine in area CA1 of the rat hippocampus. J Neurosci. 2001;21(7):2298–2307. doi: 10.1523/JNEUROSCI.21-07-02298.2001.
- Frenguelli BG, Llaudet E, Dale N. High-resolution real-time recording with microelectrode biosensors reveals novel aspects of adenosine release during hypoxia in rat hippocampal slices. J Neurochem. 2003;86(6):1506–1515. doi: 10.1046/j.1471-4159.2003.01957.x.
- Frenguelli BG, Wigmore G, Llaudet E, Dale N. Temporal and mechanistic dissociation of ATP and adenosine release during ischaemia in the mammalian hippocampus. J Neurochem. 2007;101(5):1400–1413. doi: 10.1111/j.1471-4159.2006.04425.x.
- Dale N, Frenguelli BG. Release of adenosine and ATP during ischemia and epilepsy. Curr Neuropharmacol. 2009;7(3):160–179. doi: 10.2174/157015909789152146.
- Dale N, Frenguelli BG. Measurement of purine release with microelectrode biosensors. Purinergic Signal. 2012;8(Suppl 1):27–40. doi: 10.1007/s11302-011-9273-4.
- Weigand MA, Michel A, Eckstein HH, Martin E, Bardenheuer HJ. Adenosine: a sensitive indicator of cerebral ischemia during carotid endarterectomy. Anesthesiology. 1999;91(2):414–421. doi: 10.1097/00000542-199908000-00015.
- Dale N. Delayed production of adenosine underlies temporal modulation of swimming in frog embryo. J Physiol Lond. 1998;511(Pt 1):265–272. doi: 10.1111/j.1469-7793.1998.265bi.x.
- Llaudet E, Botting NP, Crayston JA, Dale N. A three-enzyme microelectrode sensor for detecting purine release from central nervous system. Biosens Bioelectron. 2003;18(1):43–52. doi: 10.1016/S0956-5663(02)00106-9.
- Tian F, Llaudet E, Dale N. Ruthenium purple-mediated microelectrode biosensors based on sol-gel film. Anal Chem. 2007;79(17):6760–6766. doi: 10.1021/ac070822f.
- Nor AM, McAllister C, Louw SJ, Dyker AG, Davis M, Jenkinson D, Ford GA. Agreement between ambulance paramedic- and physician-recorded neurological signs with face arm speech test (FAST) in acute stroke patients. Stroke. 2004;35(6):1355–1359. doi: 10.1161/01.STR.0000128529.63156.c5.
- Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980;58(1):113–130.
- Brott T, Adams HP, Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864–870. doi: 10.1161/01.STR.20.7.864.
- Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group Alberta Stroke Programme Early CT Score. Lancet. 2000;355(9216):1670–1674. doi: 10.1016/S0140-6736(00)02237-6.
- Farrell C, Chappell F, Armitage PA, Keston P, MacLullich A, Shenkin S, Wardlaw JM. Development and initial testing of normal reference MR images for the brain at ages 65–70 and 75–80 years. Eur Radiol. 2009;19(1):177–183. doi: 10.1007/s00330-008-1119-2.
- Laghi Pasini F, Guideri F, Picano E, Parenti G, Petersen C, Varga A, Di Perri T. Increase in plasma adenosine during brain ischemia in man: a study during transient ischemic attacks, and stroke. Brain Res Bull. 2000;51(4):327–330. doi: 10.1016/S0361-9230(99)00240-3.
- Tian F, Bibi F, Dale N, Imray CHE. Blood purine measurements as a rapid real-time indicator of reversible brain ischaemia. Purinergic Signal. 2017;13(4):521–528. doi: 10.1007/s11302-017-9578-z.
Source: PubMed